DE60009931T2 - Muscarin-antagonisten - Google Patents

Muscarin-antagonisten Download PDF

Info

Publication number
DE60009931T2
DE60009931T2 DE60009931T DE60009931T DE60009931T2 DE 60009931 T2 DE60009931 T2 DE 60009931T2 DE 60009931 T DE60009931 T DE 60009931T DE 60009931 T DE60009931 T DE 60009931T DE 60009931 T2 DE60009931 T2 DE 60009931T2
Authority
DE
Germany
Prior art keywords
etoac
formula
compounds
compound according
added
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60009931T
Other languages
German (de)
English (en)
Other versions
DE60009931D1 (de
Inventor
W. John CLADER
A. Joseph KOZLOWSKI
W. Stuart MCCOMBIE
W. Michael MILLER
F. Susan VICE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of DE60009931D1 publication Critical patent/DE60009931D1/de
Publication of DE60009931T2 publication Critical patent/DE60009931T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
    • C07D211/32—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
DE60009931T 1999-09-22 2000-07-05 Muscarin-antagonisten Expired - Lifetime DE60009931T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US401391 1989-08-31
US40139199A 1999-09-22 1999-09-22
PCT/US2000/018358 WO2001021590A1 (en) 1999-09-22 2000-07-05 Muscarinic antagonists

Publications (2)

Publication Number Publication Date
DE60009931D1 DE60009931D1 (de) 2004-05-19
DE60009931T2 true DE60009931T2 (de) 2005-04-07

Family

ID=23587566

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60009931T Expired - Lifetime DE60009931T2 (de) 1999-09-22 2000-07-05 Muscarin-antagonisten

Country Status (14)

Country Link
EP (1) EP1214299B1 (enExample)
JP (1) JP2003509494A (enExample)
CN (1) CN1167682C (enExample)
AR (1) AR025459A1 (enExample)
AT (1) ATE264301T1 (enExample)
AU (1) AU5786300A (enExample)
CA (1) CA2384018C (enExample)
CO (1) CO5180624A1 (enExample)
DE (1) DE60009931T2 (enExample)
ES (1) ES2215055T3 (enExample)
HK (1) HK1043590A1 (enExample)
MX (1) MXPA02003136A (enExample)
PE (1) PE20010649A1 (enExample)
WO (1) WO2001021590A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL117149A0 (en) * 1995-02-23 1996-06-18 Schering Corp Muscarinic antagonists
CN1301972C (zh) * 2001-10-10 2007-02-28 先灵公司 作为毒覃碱拮抗剂的哌啶化合物
JPWO2004069828A1 (ja) * 2003-02-04 2006-05-25 三菱ウェルファーマ株式会社 ピペリジン化合物およびその医薬用途
EP2533645B1 (en) 2010-02-09 2016-07-27 The Johns Hopkins University Methods and compositions for improving cognitive function
WO2014078568A1 (en) 2012-11-14 2014-05-22 The Johns Hopkins University Methods and compositions for treating schizophrenia
JP6478923B2 (ja) 2013-02-07 2019-03-06 ヘプタレス セラピューティクス リミテッドＨｅｐｔａｒｅｓ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ ムスカリンｍ４受容体アゴニストとしてのピペリジン−１−イル及びアゼピン−１−イルカルボキシレート
CN105142623A (zh) 2013-03-15 2015-12-09 艾吉因生物股份有限公司 用于改善认知功能的方法和组合物
EP2968237A4 (en) 2013-03-15 2016-08-31 Univ Johns Hopkins METHOD AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION
CN107810002B (zh) 2015-05-22 2021-01-05 艾吉因生物股份有限公司 左乙拉西坦的延时释放药物组合物
HK1253029A1 (zh) 2015-11-06 2019-06-06 Neurocrine Biosciences, Inc. 作为毒蕈碱性受体4(m4)拮抗剂用於治疗神经系统疾病的n-[2-(1-苄基哌啶-4-基)乙基]-4-(吡嗪-2-基)-哌嗪-1-甲酰胺衍生物及相关化合物
EP4069367B1 (en) 2019-12-06 2024-05-15 Neurocrine Biosciences, Inc. Muscarinic receptor 4 antagonists and methods of use

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5691323A (en) * 1995-05-12 1997-11-25 Merck & Co., Inc. Muscarine antagonists
IL117149A0 (en) * 1995-02-23 1996-06-18 Schering Corp Muscarinic antagonists
US5889006A (en) * 1995-02-23 1999-03-30 Schering Corporation Muscarinic antagonists
DE69919171T2 (de) * 1998-06-30 2005-08-04 Schering Corp. Muskarin-rezeptor antagonisten
US6066636A (en) * 1998-06-30 2000-05-23 Schering Corporation Muscarinic antagonists

Also Published As

Publication number Publication date
CA2384018A1 (en) 2001-03-29
HK1043590A1 (zh) 2002-09-20
AR025459A1 (es) 2002-11-27
ES2215055T3 (es) 2004-10-01
AU5786300A (en) 2001-04-24
JP2003509494A (ja) 2003-03-11
EP1214299B1 (en) 2004-04-14
DE60009931D1 (de) 2004-05-19
CN1374949A (zh) 2002-10-16
CA2384018C (en) 2010-01-12
ATE264301T1 (de) 2004-04-15
CN1167682C (zh) 2004-09-22
PE20010649A1 (es) 2001-06-19
WO2001021590A1 (en) 2001-03-29
CO5180624A1 (es) 2002-07-30
EP1214299A1 (en) 2002-06-19
MXPA02003136A (es) 2002-09-30

Similar Documents

Publication Publication Date Title
DE69733478T2 (de) Ether-muskarinantagonisten
US6294554B1 (en) Muscarinic antagonists
DE69631370T2 (de) Benzylpiperidine und -piperazine als muscarinantagonisten
DE3142982C2 (de) Carbostyrilverbindungen, Verfahren zu deren Herstellung und Arzneimittel, welche diese enthalten
DE69111029T2 (de) Kondensierte heterocyclische Verbindungen, ihre Herstellung und Verwendung.
DE69103206T2 (de) Neue Derivate des Aminopiperidins, Aminopyrrolidins und des Aminoperhydroazepins, Verfahren zur Herstellung und diese enthaltende Arzneimittel.
DE69534213T2 (de) Therapeutisch wirksame Heterocyclen
DE69717109T2 (de) 1,4-disubstituierte piperdine als muskarin-antagonisten
DE69715865T2 (de) Muscarin-antagonisten
DE2824064A1 (de) Phthalazin-derivate, ihre herstellung und solche derivate enthaltende arzneimittel
CH649527A5 (de) 1,2-diaminocyclobuten-3,4-dione, verfahren zu deren herstellung und pharmazeutische mittel, die diese verbindungen enthalten.
EP2060569A1 (de) 3-[(2-{[4-Hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester-Methansulfonat-Hemihydrat und dessen Verwendung als Arzneimittel
TW201041868A (en) Anthelmintic agents and their use
JP2007297410A (ja) ムスカリンアンタゴニスト
DE69919171T2 (de) Muskarin-rezeptor antagonisten
EP0505868A2 (de) N-Acyl-alpha-aminosäurederivate
DE60009931T2 (de) Muscarin-antagonisten
DE69613457T2 (de) 5-(4-subst.-piperidinyl-1)-3-aryl-pentansäure derivate als tachykinin rezeptor antagonisten
DE68910999T2 (de) 1,2,3,4-Tetrahydroisoquinoline, Verfharen zu ihrer Herstellung und ihre Verwendung als Kappa-Rezeptor Agonisten.
DE69214588T2 (de) Methanoanthracene als Dopaminantagonisten
DE69733427T2 (de) Tetrahydrobezindol derivate
DE1117584B (de) Verfahren zur Herstellung von Phentiazinderivaten
DE69732762T2 (de) Indanderivate für antipsychotische mittel
DE3880077T2 (de) Mittel gegen angst.
DE2847621A1 (de) Phthalazin-derivate, verfahren zu ihrer herstellung und solche derivate enthaltende arzneimittel

Legal Events

Date Code Title Description
8332 No legal effect for de
8370 Indication related to discontinuation of the patent is to be deleted
8364 No opposition during term of opposition